We are live on
!
Find out more
GCM
Gladius Capital Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
25.75%
This Fund
S&P 500
This Quarter
Est. Return
-3.42%
1 Year Est. Return
+25.75%
3 Year Est. Return
+78.03%
5 Year Est. Return
+67.88%
10 Year Est. Return
+218.88%
AUM
$2.4B
AUM Growth
+$350M
(+17%)
Cap. Flow
+$416M
Cap. Flow
% of AUM
17.36%
Top 10 Holdings %
Top 10 Hldgs %
49.95%
Holding
464
New
103
Increased
192
Reduced
81
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$47.1M |
| 2 |
Apple
AAPL
|
+$30.8M |
| 3 |
NVIDIA
NVDA
|
+$27.4M |
| 4 |
Amazon
AMZN
|
+$24.1M |
| 5 |
Advanced Micro Devices
AMD
|
+$18.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$111M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$9.74M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$5.86M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$3.23M |
| 5 |
Walt Disney
DIS
|
+$1.17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 5.84% |
| 2 | Consumer Discretionary | 2.07% |
| 3 | Financials | 1.29% |
| 4 | Consumer Staples | 1.2% |
| 5 | Industrials | 1.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Perrigo
PRGO
$1.74B
| $25.8K | ﹤0.01% |
807
-21
| -3% | -$739 |
|
327
Atea Pharmaceuticals
AVIR
$399M
| $25.7K | ﹤0.01% |
8,581
+4,251
| +98% | +$14.5K |
|
328
Revvity
RVTY
$12.7B
| $25.7K | ﹤0.01% |
232
+106
| +84% | +$12.5K |
|
329
International Money Express
IMXI
$367M
| $25.1K | ﹤0.01% |
1,484
+229
| +18% | +$4.61K |
|
330
Zymeworks
ZYME
$1.7B
| $25K | ﹤0.01% |
3,940
+1,053
| +36% | +$7.78K |
|
331
Voyager Therapeutics
VYGR
$189M
| $24.7K | ﹤0.01% |
+3,182
| New | +$29.1K |
|
332
Orthofix Medical
OFIX
$428M
| $23.5K | ﹤0.01% |
1,831
+568
| +45% | +$10.2K |
|
|
ITOS
333
DELISTED
iTeos Therapeutics
ITOS
| $23.1K | ﹤0.01% |
2,105
+813
| +63% | +$10.4K |
|
334
Organon & Co
OGN
$3.56B
| $22.9K | ﹤0.01% |
1,318
-55
| -4% | -$1.15K |
|
|
EGRX
335
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $22.4K | ﹤0.01% |
1,421
+107
| +8% | +$1.92K |
|
336
Vanda Pharmaceuticals
VNDA
$308M
| $21.9K | ﹤0.01% |
5,074
+114
| +2% | +$633 |
|
337
Nuvation Bio
NUVB
$2.13B
| $21.6K | ﹤0.01% |
16,082
+3,198
| +25% | +$5.32K |
|
338
Vor Biopharma
VOR
$1.28B
| $21.2K | ﹤0.01% |
+500
| New | +$27.1K |
|
|
DZSI
339
DELISTED
DZS Inc. Common Stock
DZSI
| $19.9K | ﹤0.01% |
9,497
+2,827
| +42% | +$8.13K |
|
340
Vir Biotechnology
VIR
$1.48B
| $19.8K | ﹤0.01% |
+2,111
| New | +$30.1K |
|
341
Century Therapeutics
IPSC
$343M
| $19.6K | ﹤0.01% |
9,810
+3,564
| +57% | +$9.48K |
|
342
ADC Therapeutics
ADCT
$144M
| $17.7K | ﹤0.01% |
+19,752
| New | +$26.3K |
|
343
NVE Corp
NVEC
$626M
| $13.3K | ﹤0.01% |
162
+30
| +23% | +$2.52K |
|
344
Cirrus Logic
CRUS
$6.23B
| $11.8K | ﹤0.01% |
+160
| New | +$12.5K |
|
345
Genie Energy
GNE
$389M
| $11.2K | ﹤0.01% |
760
+136
| +22% | +$1.98K |
|
346
Qualcomm
QCOM
$168B
| $10.9K | ﹤0.01% |
98
+21
| +27% | +$2.44K |
|
347
Power Integrations
POWI
$3.29B
| $10.2K | ﹤0.01% |
+134
| New | +$11.5K |
|
348
Silicon Laboratories
SLAB
$7.21B
| $10.1K | ﹤0.01% |
87
+46
| +112% | +$6.35K |
|
349
AXT Inc
AXTI
$4.92B
| $9.95K | ﹤0.01% |
4,146
+672
| +19% | +$1.78K |
|
350
Consolidated Edison
ED
$40.2B
| $9.15K | ﹤0.01% |
107
+12
| +13% | +$1.09K |
|
Similar funds
ACM
CCM
BFPW
RIA
GACM
GA
LIA
Gladius Capital Management's Q3 2023 Portfolio in Review
As of Q3 2023, Gladius Capital Management held 464 positions worth $2.4B, up 17% from $2.05B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Gladius Capital Management deployed $416M of net new capital in Q3 2023, opening 103 new positions and adding to 192 existing holdings. Its largest new stake was Microsoft: 142,665 shares worth $45M.
By sector, the portfolio is most concentrated in Technology at 5.8% of assets, up from 0.43% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Deckers Outdoor, an estimated $212K trimmed.
- Gladius Capital Management's largest Q3 2023 buy was Microsoft: 142,665 shares worth $45M.
- Gladius Capital Management added most to Caterpillar in Q3 2023, an estimated $15.3M increase.
- Gladius Capital Management's biggest Q3 2023 reduction was Deckers Outdoor, cutting an estimated $212K.
- Gladius Capital Management fully exited State Street SPDR S&P 500 ETF Trust in Q3 2023, selling an estimated $111M.
- Gladius Capital Management's ten largest holdings make up 50% of its $2.4B portfolio in Q3 2023.
- Gladius Capital Management opened 103 new positions and closed 84 in Q3 2023.
- Gladius Capital Management's portfolio value rose 17% quarter-over-quarter to $2.4B.
Based on Gladius Capital Management's 13F filing for Q3 2023, filed 10 Oct 2023.